Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05904548 · ClinicalTrials.gov registry record · NA

Atrial Flutter Ablation in the iCMR

A NA study of Atrial Flutter Typical, sponsored by Imricor Medical Systems.

Recruiting
Registry status
NA
Development phase
91
Enrollment target
6
Study locations

NCT05904548 is a NA study of Atrial Flutter Typical that is actively recruiting participants, run by Imricor Medical Systems. The registered enrollment target is 91 participants. The trial reports 6 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05904548, a NA study of Atrial Flutter Typical, is actively recruiting participants, sponsored by Imricor Medical Systems.

RECRUITING
Registry status
NA
Development phase
91 participants
Enrollment target
6
Study locations

Study Summary

The VISABL-AFL clinical investigation is a prospective, single-arm, multi-center, interventional, Investigational Device Exemption (IDE) trial. The primary objectives of VISABL-AFL are to assess the safety and efficacy of radiofrequency (RF) ablation of type-I atrial flutter performed with the Vision-MR Ablation Catheter 2.0 in the iCMR environment.

Conditions Studied

Interventions

  • DEVICE RF Ablation

Study Locations (6)

Other

  • l'institut Cardiologique Paris Sud (ICPS) - Massy
  • Amsterdam University Medical Center (AUMC) - Amsterdam
  • University Hospital of Vaud (CHUV) - Lausanne

Virginia

  • University of Virginia (UVA) - Charlottesville
  • Virginia Commonwealth University - Richmond

Maryland

  • Johns Hopkins University (JHU) - Baltimore

Trial Details

FieldValue
Enrollment Target 91 participants
Start Date 2024-06-20
Est. Completion 2026-12-31
Phase NA

Sponsor

Imricor Medical Systems

1 total trials

What the Registry Record Tells You About NCT05904548

The ClinicalTrials.gov registry entry for NCT05904548 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Imricor Medical Systems, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atrial Flutter Typical appearing as the primary indexed condition, and to 1 intervention - of which RF Ablation is the first listed.

NCT05904548 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Other, Virginia, Maryland.

Frequently Asked Questions

What is clinical trial NCT05904548 about?

NCT05904548 is a clinical study titled "Atrial Flutter Ablation in the iCMR". The VISABL-AFL clinical investigation is a prospective, single-arm, multi-center, interventional, Investigational Device Exemption (IDE) trial. The primary objectives of VISABL-AFL are to assess the safety and efficacy of radiofrequency (RF) ablation of type-I atrial flutter performed with the Visio...

What is the current status of trial NCT05904548?

This trial is currently recruiting. It is a NA study. The enrollment target is 91 participants. The study started on 2024-06-20. Estimated completion is 2026-12-31.

What conditions does trial NCT05904548 study?

This clinical trial studies the following conditions: Atrial Flutter Typical.

What interventions are being tested in trial NCT05904548?

The interventions under investigation include: RF Ablation (DEVICE).

Who is sponsoring clinical trial NCT05904548?

This trial is sponsored by Imricor Medical Systems, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05904548 being conducted?

This trial has 6 study locations across Maryland, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.